26834 Secukinumab demonstrated sustained effectiveness in moderate-to-severe plaque psoriasis across weight categories: 36-month data from PURE
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI